glp-1 small molecule agonist Emerging Trends in the Development of Receptor Agonists Current Insights, Advantages and Challenges

GLP-1 RAs could offer a novel therapeutic approach for treating MS

This makes Cagrilintide an interesting research object within studies on eating behavior, satiety and weight-related processes

Human outcome data remains limited relative to the enthusiasm around NAD+, so it is ranked as a mechanistically compelling but clinically unproven research compound

Endometriosis: Early research suggests that GLP1 medications appear to have antiinflammatory and antifibrotic properties that could help the reproductive system

RGN-259 treatment promoted rapid healing of corneal epithelial defects, improved Mackie classification disease stage, and produced significant improvements in ocular discomfort, foreign body sensation, and dryness, with no significant adverse effects

doi:10.7748/ns.2021.e11709 2